Last reviewed · How we verify
Juvenile Idiopathic Arthritis with Oligoarticular Course — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| tumor necrosis factor inhibitors (TNFi) | tumor-necrosis-factor-inhibitors-tnfi | Pfizer | biologic | tumor necrosis factor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Juvenile Idiopathic Arthritis with Oligoarticular Course
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Juvenile Idiopathic Arthritis with Oligoarticular Course:
- Juvenile Idiopathic Arthritis with Oligoarticular Course treatment updates — RSS
- Juvenile Idiopathic Arthritis with Oligoarticular Course treatment updates — Atom
- Juvenile Idiopathic Arthritis with Oligoarticular Course treatment updates — JSON
Cite this brief
Drug Landscape (2026). Juvenile Idiopathic Arthritis with Oligoarticular Course — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/juvenile-idiopathic-arthritis-with-oligoarticular-course. Accessed 2026-06-10.
Related
- Juvenile Idiopathic Arthritis with Oligoarticular Course full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing